- Home
- KMI vs TNGX Comparison
KMI vs TNGX Comparison
Compare KMI & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KMI
- TNGX
- Stock Information
- Founded
- KMI 1936
- TNGX 2014
- Country
- KMI United States
- TNGX United States
- Employees
- KMI N/A
- TNGX N/A
- Industry
- KMI Natural Gas Distribution
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- KMI Utilities
- TNGX Health Care
- Exchange
- KMI Nasdaq
- TNGX Nasdaq
- Market Cap
- KMI 58.3B
- TNGX 1.0B
- IPO Year
- KMI 2011
- TNGX N/A
- Fundamental
- Price
- KMI $26.14
- TNGX $8.04
- Analyst Decision
- KMI Buy
- TNGX Strong Buy
- Analyst Count
- KMI 13
- TNGX 6
- Target Price
- KMI $31.23
- TNGX $10.80
- AVG Volume (30 Days)
- KMI 15.5M
- TNGX 4.4M
- Earning Date
- KMI 10-22-2025
- TNGX 11-04-2025
- Dividend Yield
- KMI 4.48%
- TNGX N/A
- EPS Growth
- KMI 7.28
- TNGX N/A
- EPS
- KMI 1.22
- TNGX N/A
- Revenue
- KMI $16,416,000,000.00
- TNGX $66,501,000.00
- Revenue This Year
- KMI $11.56
- TNGX $20.41
- Revenue Next Year
- KMI $5.11
- TNGX N/A
- P/E Ratio
- KMI $21.40
- TNGX N/A
- Revenue Growth
- KMI 8.35
- TNGX 53.29
- 52 Week Low
- KMI $23.94
- TNGX $1.03
- 52 Week High
- KMI $31.48
- TNGX $9.70
- Technical
- Relative Strength Index (RSI)
- KMI 40.21
- TNGX 50.66
- Support Level
- KMI $25.66
- TNGX $7.12
- Resistance Level
- KMI $26.40
- TNGX $8.17
- Average True Range (ATR)
- KMI 0.56
- TNGX 0.71
- MACD
- KMI -0.06
- TNGX -0.09
- Stochastic Oscillator
- KMI 21.39
- TNGX 49.07
About KMI Kinder Morgan Inc.
Kinder Morgan operates natural gas, crude oil, and refined products pipelines connecting producing regions to demand centers. It is principally involved in the gathering, storage, and transmission of natural gas across the continental United States. It also operates distribution centers for refined products along with the largest fleet of Jones Act-compliant tankers.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.